CatalystMarker
← board

INO

Inovio Pharmaceuticalsdistress 10/10 · high distress / dilution risk
$1.03-2%today-64% from 52w high
inovio.com112 employeesFounded 1983Plymouth Meeting, PABiotechnology
Oncology 1
Lead: Glioblastoma · target PD-L1
Revenue
pre-revenue
Liquidity
$38M
Runway
0.5 yrs
Shares 1y
+55%

Price & events

-33.7% over 6M
$1.03$1.46$1.89Jan 26Apr 26Jul 2621.0Mdilution: EFFECT shelf_effective (2026-07-10)dilution: S-3 shelf_registration (2026-07-02)dilution: 424B5 offering (2026-04-02)dilution: 424B5 offering (2026-04-02)dilution: 424B5 offering (2026-01-27)financing: 8-K material_agreement (2026-04-06)financing: 8-K material_agreement (2026-01-27)rating: HC Wainwright & Co.: Neutral (2026-06-01)
CatalystRating changeDilutionFinancingdashed = today
-2.4%
1D
-7.6%
1W
-8.4%
1M
-9.2%
3M
-31.5%
6M
-33.7%
1Y
-90.7%
2Y
-98.9%
5Y
-99.1%
All

Overview

Market Cap
$85.15M
Volume
383.00K
52 Week Range
$1.03 – $2.87
Total Shares
82.27M
Float Shares
81.88M
Short %
20.87%
% Held by Insiders
0.42%
% Held by Institutions
47.30%
RVOL
0.28x
Beta
1.49

Pipeline stages · 1 programs

INO-5401, INO-9012, Cemiplimab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2026-12-31

Pipeline · 2 trials · 1 upcoming

ReadoutPhaseDrugIndicationEnrollStatus
2026-12-31
Estimated 50%
readout ~2027-02-14
Phase 1/2INO-5401, INO-9012, CemiplimabbreakthroughorphanGlioblastoma—active not recruiting
2025-05-09
Phase 1/2INO-5401, INO-9012, AtezolizumabbreakthroughorphanUrothelial Carcinoma35completed

Upcoming readouts & decisions · our signals

1 upcoming event has our read — the sell-the-news timing call plus an experimental clinical estimate. Go Pro to see them.

Catalyst news & presentations · 2

Approved drugs (0)

  • none — clinical-stage

Capital structure — dilution & financing

Shares out: 82,273,237 · 5 offerings/1y · 0 PIPEs
  • 2026-07-10EFFECTshelf_effective
  • 2026-07-02S-3shelf_registration
  • 2026-04-068-Kmaterial_agreement
  • 2026-04-02424B5offering
  • 2026-04-02424B5offering
  • 2026-01-278-Kmaterial_agreement
  • 2026-01-27424B5offering
🔒 Positioning — Pro
Short interest / days-to-cover, insider buys & sells.
Upgrade to Pro
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to Pro

Wall St ratings

hold · target $3 (+232% upside) · 3 analysts
  • 2026-06-01HC Wainwright & Co.Neutral
  • 2025-11-14Piper SandlerOverweight
  • 2025-08-14HC Wainwright & Co.Neutral
  • 2025-07-09Piper SandlerOverweight
  • 2025-05-14RBC CapitalSector Perform
  • 2025-05-14OppenheimerOutperform

Competitors — PD-L1

  • IBRXImmunityBio, Inc.$7.8B · D5
  • REPLReplimune Group, Inc.$906M · D2
  • CHRSCoherus Oncology, Inc.$218M · D7
  • GNPXGenprex, Inc.$86M · D6
  • LSTALISATA THERAPEUTICS, INC.$20M · D4
  • ANLAdlai Nortye Ltd.— · D5
  • AZNASTRAZENECA PLC— · D3

Recent news

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.